Abbott Laboratories (ABT) Accumulated Expenses (2009 - 2026)

Abbott Laboratories has disclosed Accumulated Expenses across 18 years of filings, most recently posting $1.6 billion for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 4.45% year-over-year to $1.6 billion; the TTM figure through Jun 2026 stood at $1.6 billion (up 4.45% YoY), while the FY2025 annual figure was $1.7 billion, up 2.59% from the prior year.
• Accumulated Expenses came in at $1.6 billion for Q2 2026 at Abbott Laboratories, up from $1.2 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.7 billion in Q4 2025 to a low of $1.1 billion in Q1 2024.
• Average Accumulated Expenses over 5 years is $1.4 billion, with a median of $1.5 billion recorded in 2022.
• Year-over-year, Accumulated Expenses declined 4.27% in 2023 and increased 11.59% in 2025.
• Over 5 years, Accumulated Expenses stood at $1.6 billion in 2022, then advanced by 2.63% to $1.6 billion in 2023, then increased by 6.51% to $1.7 billion in 2024, then increased by 2.59% to $1.7 billion in 2025, then fell by 7.22% to $1.6 billion in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $1.6 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.7 billion in Q4 2025.